|
|
|
|
|
|
|
16.12.25 - 08:01
|
Enhertu approved in US for 1L HER2+ metastatic BC (Cision)
|
|
|
16 December 2025
Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo's Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of more than three years
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.10.25 - 09:01
|
AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-Generation Antibody Therapeutics (Cision)
|
|
|
Stockholm, Sweden, Oct 22, 2025 – Swedish biotech company AAX Biotech AB announces a collaboration with Daiichi Sankyo, one of the global leaders in antibody-drug conjugates (ADCs). The collaboration marks a significant milestone for AAX Biotech, underscoring the potential of its proprietary Opti-mAb[®] technology for innovative antibody therapeutics.
[AAX-Biotech-Daiichi-Sankyo-collaboration-Opti-mAb.png]
AAX Biotech pioneers innovative technologies that advance the development of next-generation antibody therapeutics. Its two platforms, Seqitope[®] and Opti-mAb[®], address key...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.09.25 - 08:30
|
Enhertu improved IDFS in early BC in DB-05 (Cision)
|
|
|
29 September 2025
Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial in patients with high-risk early breast cancer following neoadjuvant therapy
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo's Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Results from the DESTINY-Breast05 and DESTINY-Breast11 trials
will be presented at ESMO 2025 in a Presidential...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
